Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase

Nature Structural and Molecular Biology

Volumn 21, Issue 7, 2014, Pages 579-584

  Shan, Yibing ^a   Gnanasambandan, Kavitha ^b   Ungureanu, Daniela ^c   Kim, Eric T ^a   Hammarén, Henrik ^c   Yamashita, Kazuo ^d   Silvennoinen, Olli ^c   Shaw, David E ^a,e   Hubbard, Stevan R ^b  

^a D E SHAW RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d OSAKA UNIVERSITY   (Japan)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHOSPHOTRANSFERASE; PSEUDOKINASE; UNCLASSIFIED DRUG;

CATALYST; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTAGENESIS; MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

BINDING SITES; COMPUTER SIMULATION; HUMANS; JANUS KINASE 2; MODELS, GENETIC; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84903899364     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2849     Document Type: Review

References (42)

1. O'Shea, J.J., Holland, S.M. & Staudt, L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 368, 161-170 (2013).
2. Wallweber, H.J., Tam, C., Franke, Y., Starovasnik, M.A. & Lupardus, P.J. Structural basis of recognition of interferon-a receptor by tyrosine kinase 2. Nat. Struct. Mol. Biol. 21, 443-448 (2014).
3. Vainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118, 1723-1735 (2011).
4. Haan, C., Behrmann, I. & Haan, S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell. Mol. Med. 14, 504-527 (2010).
5. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
6. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myelopro-liferative disorders. Lancet 365, 1054-1061 (2005).
7. Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
8. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
9. Saharinen, P. & Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963 (2002).
10. Saharinen, P., Takaluoma, K. & Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395 (2000).
11. Ungureanu, D. et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-976 (2011).
12. Bandaranayake, R.M. et al. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759 (2012).
13. Shan, Y. et al. How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133, 9181-9183 (2011).
14. Dusa, A., Mouton, C., Pecquet, C., Herman, M. & Constantinescu, S.N. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS ONE 5, e11157 (2010).
15. Liang, S., Liu, S., Zhang, C. & Zhou, Y. A simple reference state makes a significant improvement in near-native selections from structurally refined docking decoys. Proteins 69, 244-253 (2007).
16. Liang, S., Zhang, C., Sarmiento, J. & Standley, D.M. Protein loop modeling with optimized backbone potential functions. J. Chem. Theory Comput. 8, 1820-1827 (2012).
17. Argetsinger, L.S. et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967 (2004).
18. Feener, E.P., Rosario, F., Dunn, S.L., Stancheva, Z. & Myers, M.G. Tyrosine phos-phorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978 (2004).
19. Zhao, L. et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J. Biol. Chem. 284, 26988-26998 (2009).
20. 523 inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26, 4063-4073 (2006).
21. Mazurkiewicz-Munoz, A.M. et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol. Cell. Biol. 26, 4052-4062 (2006).
22. Mullighan, C.G. et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 106, 9414-9418 (2009).
23. Wan, X., Ma, Y., McClendon, C.L., Huang, L.J. & Huang, N. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure. PLoS Comput. Biol. 9, e1003022 (2013).
24. Miyazawa, S. & Jernigan, R.L. Residue-residue potentials with a favorable contact pair term and an unfavorable high packing density term, for simulation and threading. J. Mol. Biol. 256, 623-644 (1996).
25. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
26. Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002).
27. Shan, Y. et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl. Acad. Sci. USA 106, 139-144 (2009).
28. Gnanasambandan, K., Magis, A. & Sayeski, P.P. The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617. Biochemistry 49, 9972-9984 (2010).
29. Lindauer, K., Loerting, T., Liedl, K.R. & Kroemer, R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37 (2001).
30. Wan, S. & Coveney, P.V. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations. J. Chem. Inf. Model. 52, 2992-3000 (2012).
31. Toms, A.V. et al. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20, 1221-1223 (2013).
32. Lupardus, P.J., et al. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. USA 111, 8025-8030 (2014).
33. LaFave, L.M. & Levine, R.L. JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol. Sci. 33, 574-582 (2012).
34. Baffert, F. et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol. Cancer Ther. 9, 1945-1955 (2010).
35. 2 dihedral angles. J. Chem. Theory Comput. 8, 3257-3273 (2012).
36. Mackerell, A.D. Jr. et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616 (1998).
37. Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W. & Klein, M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
38. Shaw, D.E. et al. in Proc. of the ACAM/IEEE Conference on Supercomputing Vol. 51, 91-97 (ACM Press, New York, 2008).
39. Hoover, W.G. Canonical dynamics: equilibrium phase-space distributions. Phys. Rev. A 31, 1695-1697 (1985).
40. Lippert, R.A. et al. A common, avoidable source of error in molecular dynamics integrators. J. Chem. Phys. 126, 046101 (2007).
41. Krautler, V., Van Gunsteren, W.F. & Hunenberger, P.H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 22, 501-508 (2001).
42. Fennell, C.J. & Gezelter, J.D. Is the Ewald summation still necessary? Pairwise alternatives to the accepted standard for long-range electrostatics. J. Chem. Phys. 124, 234104 (2006).